Brief: ASIT Biotech Finalizes Industrialization Process For The Manufacture Of Clinical Batches Of Hdm-ASIT+

European Medical Solutions SA

17/12/2018 06:08

Dec 17 (Reuters) - ASIT BIOTECH SA  ASIT.BR :
    * ASIT BIOTECH REACHES ANOTHER KEY MILESTONE BY FINALIZING
THE
INDUSTRIALIZATION PROCESS FOR THE MANUFACTURE OF CLINICAL
BATCHES OF ITS HDM-ASIT+™ PRODUCT CANDIDATE FOR HOUSE DUST MITE
ALLERGY
    * COMPANY PLANS TO SUBMIT AN APPLICATION FOR A FIRST-IN-MAN
CLINICAL TRIAL AUTHORIZATION BY END OF FIRST HALF OF 2019
    * THIS CRUCIAL STEP HAS ALLOWED COMPANY TO LAUNCH FINAL
PRECLINICAL DEVELOPMENTS REQUIRED BY AUTHORITIES AHEAD OF A
CLINICAL TRIAL
    * PLANS TO SUBMIT AN APPLICATION FOR A FIRST-IN-MAN CLINICAL
TRIAL
AUTHORIZATION BY END OF FIRST HALF OF 201
    * FIRST BATCH OF HDM-ASIT+™ WAS MANUFACTURED ON ASIT
BIOTECH'S NEW
UNIT FOR PRODUCING GMP(1)-COMPLIANT CLINICAL BATCHES FOR PHASE I
AND II STUDIES

Source text for Eikon:  ID:nBw5Ntx8Ma 
Further company coverage:  ASIT.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))